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Abstract
Interleukin-11 (IL-11) is a pleiotropic cytokine with both pro- and anti-inflammatory 
properties. It activates its target cells via binding to the membrane-bound IL-11 re-
ceptor (IL-11R), which then recruits a homodimer of the ubiquitously expressed, 
signal-transducing receptor gp130. Besides this classic signaling pathway, IL-11 can 
also bind to soluble forms of the IL-11R (sIL-11R), and IL-11/sIL-11R complexes 
activate cells via the induction of gp130 homodimerization (trans-signaling). We 
have previously reported that the metalloprotease ADAM10 cleaves the membrane-
bound IL-11R and thereby generates sIL-11R. In this study, we identify the rhom-
boid intramembrane protease RHBDL2 as a so far unrecognized alternative sheddase 
that can efficiently trigger IL-11R secretion. We determine the cleavage site used by 
RHBDL2, which is located in the extracellular part of the receptor in close proximity 
to the plasma membrane, between Ala-370 and Ser-371. Furthermore, we identify 
critical amino acid residues within the transmembrane helix that are required for IL-
11R proteolysis. We also show that ectopically expressed RHBDL2 is able to cleave 
the IL-11R within the early secretory pathway and not only at the plasma membrane, 
indicating that its subcellular localization plays a central role in controlling its activ-
ity. Moreover, RHBDL2-derived sIL-11R is biologically active and able to perform 
IL-11 trans-signaling. Finally, we show that the human mutation IL-11R-A370V 
does not impede IL-11 classic signaling, but prevents RHBDL2-mediated IL-11R 
cleavage.
K E Y W O R D S
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1 |  INTRODUCTION
The cytokine interleukin-11 (IL-11) is a pleiotropic cyto-
kine with several reported pro- as well as anti-inflamma-
tory properties.1,2 IL-11 is a member of the IL-6 family 
of cytokines, which all share usage of the ubiquitously ex-
pressed signal-transducing receptor gp130.3 Specificity is 
gained through a non-signaling IL-11 receptor (IL-11R), 
to which IL-11 initially binds and thereby induces gp130 
homodimerization. IL-11 activates several important in-
tracellular signaling cascades, among them the Janus ki-
nase/signal transducer and activator of transcription (Jak/
STAT), the phosphoinositide 3-kinase (PI3K), and the mi-
togen-activated protein kinase (MAPK) pathway. IL-11 is 
secreted from a variety of cell types, including fibroblasts 
and epithelial cells of different origin.4 The most import-
ant inducer of IL-11 production appears to be transforming 
growth factor β (TGFβ).5
IL-11 has been initially regarded as an anti-inflammatory 
cytokine and as a recombinant protein is approved by the 
FDA for the treatment of chemotherapy-induced thrombo-
cytopenia.6 However, this view has changed in recent years, 
and the pro-inflammatory properties of the cytokine have 
gained more attention. Distinct tumor entities, for example, 
in the stomach,7,8 in the colon,9 or in the female breast10 rely 
primarily on IL-11 signaling, which often cannot be com-
pensated for by other cytokines like IL-6. First studies with 
IL-11 muteins9 or antibodies that block IL-11 signaling11 
have demonstrated that targeting IL-11 might be a suitable 
strategy to treat these kinds of cancers.
Besides this, IL-11 signaling is required for different 
aspects of development. It is necessary for female fertility, 
because female Il11ra–/– mice are infertile due to a failure 
of embryo implantation in the uterus.12-14 Furthermore, sig-
naling via the IL-11R is required for the correct formation of 
the skull and for tooth development. Patients with mutations 
within the IL11RA gene display craniosynostosis, a disease 
characterized by premature closures of the sutures lining 
the head bones.15-19 Some of the patients also present with 
delayed tooth eruption and supernumerary teeth within the 
jaw, but whether this is a general phenomenon is currently 
unclear.16 The underlying mechanism, at least for some of 
the patient mutations, is impaired maturation of the IL-11R, 
which prevents the transport of the receptor to the cell sur-
face and results in a complete blockade of IL-11 signaling.20 
The studied IL-11R mutants are all trapped within the ER, 
probably due to a folding defect that causes retention in the 
endoplasmic reticulum (ER),20 but it is not known whether 
this holds true for all patient mutations.
Besides the classic signaling pathway, in which IL-11 
uses the membrane-bound IL-11R, we have shown that 
IL-11 can also induce signaling via soluble forms of the 
IL-11R (sIL-11R).21,22 We have named this pathway 
IL-11 trans-signaling and found that the metalloprotease 
ADAM10 is capable of cleaving the membrane-bound IL-
11R, and thus, releasing biologically active sIL-11R.23,24 
Although the exact cleavage site within the IL-11R has not 
yet been determined, we could show that Arg-355, located 
in the juxtamembrane region which connects the three 
extracellular domains with the transmembrane region, is 
important for ADAM10-mediated cleavage and release of 
the ectodomain.23 The remaining C-terminal IL-11R trans-
membrane-spanning stub generated by this shedding event 
is afterward cleaved by the γ-secretase complex and prob-
ably degraded.25
Free sIL-11R binds IL-11, and the resulting IL-11/sIL-
11R complexes can bind to and activate gp130 homodimers 
on target cells. IL-11 trans-signaling significantly widens the 
number of cell types that can be activated by IL-11, because 
the cells do not need to express membrane-bound IL-11R. 
We have further shown that sgp130Fc (Olamkicept), which is 
the extracellular part of gp130 dimerized by the Fc part of a 
human IgG antibody that was originally developed as a spe-
cific inhibitor of IL-6 trans-signaling and that is currently in 
phase II clinical trials for patients with inflammatory bowel 
disease,26 blocks IL-11 trans-signaling, but not classic signal-
ing.23 Moreover, we have detected sIL-11R in the serum of 
healthy volunteers via ELISA,23 and IL-11R was also shown 
via an aptamer-based multiplex protein assay to be part of the 
human plasma proteome.27
Rhomboids are intramembrane serine proteases initially 
found in Drosophila as the proteases that activate the epider-
mal growth factor receptor (EGFR) pathway by cleaving the 
membrane-bound EGFR ligands.28 In mammals, rhomboid 
proteases can be subdivided into the secretase class (located 
in the secretory pathway and at the plasma membrane) and 
PARL (presenilins-associated rhomboid-like protein, located 
in mitochondria).29,30 The mammalian rhomboid secre-
tases are called Rhomboid-Like 1 (RHBDL1), RHBDL2, 
RHBDL3, and RHBDL4. The best characterized member 
of the family is RHBDL2, which is located primarily at the 
plasma membrane and for which several substrates have been 
described, including EGF,31 the C-type lectin family mem-
bers thrombomodulin,32 and CLEC14A,33 ephrin-B2,34 the 
IL-6R,35 the EGFR,36 and different cadherins.37 However, for 
most of these substrates RHBDL2-mediated cleavage in vivo 
remains to be demonstrated.
In this study, we identify the IL-11R as a novel substrate 
of RHBDL2. We map the cleavage site used by the protease 
and show that certain amino acid residues within the trans-
membrane helix (TMH) of the IL-11R are crucial for proteol-
ysis. The sIL-11R released by RHDBL2 is biologically active 
and able to induce IL-11 trans-signaling. This work identifies 
a second important protease besides ADAM10 for the induc-
tion of IL-11 trans-signaling, which could be relevant for un-
derstanding the biological functions of IL-11 in vivo.
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2 |  MATERIALS AND METHODS
2.1 | Cells and reagents
HEK293 and HeLa cells were cultured in DMEM high-glu-
cose culture medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% of fetal bovine serum, penicillin 
(60 mg/L), and streptomycin (100 mg/L). Ba/F3-gp130 cells 
were also cultured in DMEM high-glucose culture medium 
(Gibco/Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% of fetal bovine serum, penicillin 
(60 mg/L), streptomycin (100 mg/L), and additional 10 ng/
mL Hyper-IL-6. All cells were kept at 37°C and 5% of CO2 
in a standard incubator with a water-saturated atmosphere. 
Marimastat, ionomycin and 3,4-dichloroisocoumarin (DCI) 
were purchased from Sigma-Aldrich. The following antibod-
ies were used: anti-HA-tag (C29F4), anti-myc-tag (71D10), 
anti-myc-tag (9B11), and anti-α-actinin (D6F6) were pur-
chased from Cell Signaling Technology (Frankfurt/M., 
Germany). The fluorescently labeled antibodies anti-mouse-
IgG-Alexa Fluor 488, anti-rabbit-IgG-Alexa Fluor 488, and 
anti-rabbit-IgG-Alexa Fluor 594 were obtained from life 
technologies/Thermo Fisher Scientific. The fluorescently 
labeled antibodies anti-mouse-IgG-IRDye 680RD, anti-
rabbit-IgG-IRDye 680RD, anti-mouse-IgG-IRDye 800CW, 
and anti-rabbit-IgG-IRDye 800CW were purchased from LI-
COR Biosciences (Lincoln, NE, USA).
2.2 | Construction of expression plasmids
pcDNA3.1 expression plasmids for myc-tagged hIL-
11R have been described previously.38 Expression plas-
mids encoding the IL-11R variants IL-11R-KKSS and 
IL-11R-R296W have been described previously.20 The 
IL-11R deletion variants IL-11R-ΔV363_L372 and IL-
11R-ΔH353_S362 have been described previously.23,39 
All other IL-11R mutants used in this study were gener-
ated via splicing by overlapping extension (SOE)-PCR 
using pcDNA3.1-myc-hIL-11R as template. pcDNA3.1 
expression plasmids for hIL-6R have been described previ-
ously,40,41 and a variant with an N-terminal myc-tag was 
used in this study.
pcDNA3.1 expression plasmids encoding HA-tagged 
mouse RHBDL1, RHBDL2, RHBDL3, and RHBDL4 were 
kindly provided by Dr Matthew Freeman (Sir William Dunn 
School of Pathology, Oxford, UK31). The RHBDL2-SA 
mutant was generated via splicing by overlapping exten-
sion (SOE)-PCR using pcDNA3.1-mRHBDL2-HA as tem-
plate. Expression plasmids encoding RHBDL2-KDEL and 
RHDBL2-KDEL-SA were generated by PCR fusing the pep-
tide sequence KDELKDELKDEL to the C-terminus in order 
to ensure efficient retrieval to the ER.
2.3 | IL-11R proteolysis by RHDBL2 in 
HEK293 cells
In order to analyze IL-11R cleavage, 2 × 106 HEK293 cells 
were transiently transfected with the desired plasmids using 
TurboFect according to the manufacturer's instructions. IL-
11R proteolysis in HEK293 cells was in principle analyzed 
as described previously.23 Forty-eight hours after transfection, 
medium was exchanged with serum-free medium and after 
4 hours the supernatants and cells were harvested and prepared 
for analysis by western blotting. After filtration and centrifu-
gation at 1200g, the supernatants were precipitated with 20% 
of trichloroacetic acid, centrifuged at 18 000g, pellets washed 
with acetone, and centrifuged again at 18 000g. The pellet was 
boiled afterward in Laemmli buffer. The cells were washed 
in PBS and finally lysed in 300 µL lysis buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton-X-100, complete pro-
tease inhibitor cocktail (Roche Applied Science, Mannheim, 
Germany)). Cell lysates were also boiled in Laemmli buffer 
and samples loaded onto a 10% of SDS gel, run for 2 hours 
at 110 V and transferred onto a nitrocellulose membrane (GE 
Healthcare, Munich, Germany) via semidry blot using the 
Trans-Blot-Turbo (Bio-Rad, Hercules, CA, USA) at 1 A and 
constant 25 V for 40 minutes. The membrane was blocked in 
50% Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, 
NE, USA) in TBS for 1 hour at room temperature, washed in 
TBS-T and subsequently incubated with primary antibodies 
in 5% of BSA in TBS overnight at 4°C. The following day 
the membrane was washed in TBS-T and incubated with dif-
ferent IRDye-labeled secondary antibodies for 1 hour at room 
temperature. The membrane was washed again in TBS-T and 
proteins were detected with the Odyssey Fc Imager (LI-COR 
Biosciences, Lincoln, NE, USA).
2.4 | IL-11R proteolysis by ADAM10 in 
HEK293 cells
IL-11R proteolysis by ADAM10 in transiently transfected 
HEK293 cells was analyzed as described previously.23 In 
short, 48 hours after transfection, medium was removed and 
cells were washed with PBS. Afterward, cells were incubated 
with 4 mL serum-free medium and stimulated with 1 µM of 
ionomycin or DMSO as negative control for 1 hour at 37°C. 
Supernatants and cells were harvested and prepared for west-
ern blot analysis as described above.
2.5 | Immunofluorescence staining of IL-
11R and RHBDL2
HeLa cells were transfected either with pcDNA3.1-myc-IL-
11R or pcDNA3.1-HA-mRHBDL2 or co-transfected with 
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both plasmids before being seeded onto coverslips. Two days 
after transfection, cells were washed in PBS, fixed in 4% of 
paraformaldehyde in PBS for 10 minutes at room temperature, 
washed in PBS and incubated in 0.12% (w/v) glycine in PBS, 
washed again, and blocked in 10% of FCS in PBS for 30 min-
utes at room temperature. Surface IL-11R was stained with 
anti-myc-tag antibody (9B11) for 1 hour at 4°C. To remove 
unbound antibody, the cells were washed three times in PBS 
before the cells were permeabilized and blocked in 10% of 
FCS, 0.2% of saponin in PBS for 30 minutes at room temper-
ature. Afterward, the cells were incubated with anti-HA-tag 
antibody for 1 hour at room temperature in order to stain sur-
face-bound and intracellular RHBDL2. After washing three 
times with 10% of FCS and 0.2% of saponin in PBS, the cells 
were incubated with the fluorophore-labeled antibodies anti-
mouse-IgG-Alexa Flour 488 and anti-rabbit-IgG-Alexa Flour 
594 for 1 hour at room temperature and in darkness. Finally, 
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and once in ddH2O and mounted onto microscopy slides using 
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher 
Scientific, Waltham, MA, USA). Images were taken using the 
Olympus FV1000 confocal laser scanning microscope.
2.6 | Measurement of cell surface 
expression of IL-11R by flow cytometry
In order to quantify the cell surface expression of IL-11R 
and the different IL-11R variants, 0.35 × 106 HEK293 cells 
per well of a 6-well plate were transiently transfected with 
pcDNA3.1-myc-IL-11R or the respective variants. Two 
days after transfection, the cells were washed with FACS 
buffer (1% BSA in PBS) and incubated with the primary 
antibody anti-myc-tag (71D10) diluted 1:100 in FACS 
buffer for 1  hour on ice. After two washing steps with 
FACS buffer, the cells were incubated with the secondary 
antibody anti-rabbit-IgG-Alexa Flour 488 (diluted 1:100 
in FACS buffer) for 1  hour on ice and in darkness. The 
cells were washed and resuspended in FACS buffer and 
analyzed using the BD FACSCanto II (Becton Dickinson, 
Franklin Lake, NJ, USA).
2.7 | Cell viability assay with Ba/F3-
gp130 cells
HEK293 cells were transiently co-transfected with 
pcDNA3.1-myc-IL-11R or other IL-11R variants as indi-
cated together with pcDNA3.1-HA-mRHBDL2. Two days 
later, the supernatants were harvested and stored at −18°C 
until further analysis. For the viability assay, 5000 Ba/F3-
gp130 cells per well were seeded in a 96-well plate and 
incubated with the described conditioned media containing 
10% of collected supernatants from transfected and untrans-
fected HEK293 cells. Where indicated, 500  ng/mL IL-11 
or 10  ng/mL Hyper-IL-6, respectively, were added to the 
conditioned media. After 48 hours, cell viability of the Ba/
F3-gp130 cells was determined via the CellTiter-Blue Cell 
Viability Assay (Promega, Madison, WI, USA) according to 
the manufacturer's instructions and as described previously.42
2.8 | Cell viability assay with HEK293 cells
Cell viability after treatment with marimastat (Sigma-Aldrich, 
St. Louis, USA) or DCI (biomol, Hamburg, Germany) was 
determined using CellTiter-Blue Cell Viability Assay. 1.8 × 
106 HEK293 cells were seeded in a 10 cm dish and transiently 
transfected with expression plasmids encoding myc-IL-11R 
and HA-mRHBDL2 the next day using TurboFect. One day 
later, cells were detached and transferred into a 96-well plate 
in 100 µL medium. Ten hours later, different amounts of ma-
rimastat (0.01-10 µM) or DCI (0.02-20 µM) in triplicate were 
added overnight. The following day, 20 µL CellTiter-Blue were 
given to each well and fluorescence intensity (RLU; relative 
light units) was measured at λem = 590 nm for 2 hours at 37°C.
3 |  RESULTS
3.1 | RHBDL2, but not the other rhomboid 
proteases, cleaves the IL-11R
The epidermal growth factor (EGF) has been identified as a 
RHBDL2 substrate in mammalian cells.31 The cleavage site 
was located in the extracellular part of the protein in close 
F I G U R E  1  The IL-11R is a substrate for RHDBL2. A, Juxtamembrane and transmembrane region of human EGF (from Trp-1026 to 
Arg-1064) and human IL-11R (from Ser-362 to Gly-400). The RHBDL2 cleavage site within EGF with an alanine residue at the P1 positions 
(highlighted red)31 is indicated with a black arrowhead, the corresponding potential RHDBL2 cleavage sites within the IL-11R are indicated with 
black arrowheads and a question marks. The alanine residue at the P1 positions are highlighted in bold and red font. The amino acid residues 
belonging to the TMHs are underlined. B, HEK293 cells were co-transfected with expression plasmids encoding either RHDBL1, RHBDL2, 
RHBDL3, or RHBDL4 and an expression plasmid encoding either human IL-11R or control as indicated. Proteolysis of the IL-11R and expression 
of the four rhomboid proteases was analyzed by western blotting of cell lysates. Actinin was visualized as loading control. sIL-11R was precipitated 
from cell culture supernatant by TCA precipitation and also analyzed by western blot. C, HEK293 cells were transfected with IL-11R, RHDBL2 
wt, the inactive variant RHBDL2-SA, or IL-11R in combination with both RHDBL2 variants as indicated. The experiment was performed as 
described for panel b. D, HEK293 cells were co-transfected with expression plasmids encoding either RHDBL1, RHBDL2, RHBDL3, or RHBDL4 
and an expression plasmid encoding human IL-6R as indicated. Proteolysis of the IL-6R was analyzed by western blotting of cell lysates. Actinin 
was visualized as loading control. sIL-6R was precipitated from cell culture supernatant by TCA precipitation and also analyzed by western blot. E, 
HEK293 cells were co-transfected with expression plasmids encoding IL-11R and RHDBL2. Cells were treated with the rhomboid inhibitor DCI 
at a concentration of 20 µM overnight when indicated. Afterward, cells and supernatant were analyzed as described for panel b. F, HEK293 cells 
were co-transfected with an expression plasmid encoding IL-11R or co-transfected with expression plasmids encoding IL-11R and RHDBL2. The 
experiment was in principle performed as described for panels b and e, but cells were treated with the broad-spectrum metalloprotease inhibitor 
marimastat (MM, 10 µM) or the ADAM10 inhibitor GI254023X (GI, 3 µM) for 4 hours were indicated. G, 1.8 × 106 HEK293 cells were seeded 
in a 10 cm dish and transiently transfected with expression plasmids encoding IL-11R and RHBDL2. One day later, cells were detached and 
transferred into a 96-well plate in 100 µL medium. Ten hours later, different amounts of marimastat (0.01-10 µM) or DCI (0.02-20 µM) in triplicate 
were added overnight and cell viability determined the following day. SN: supernatant
6 of 15 |   KOCH et al.
proximity to the plasma membrane and contained an alanine 
residue at the P1 position (Figure  1A and31). Intriguingly, 
the IL-11R contains two such alanine residues in close 
proximity to the plasma membrane, which could be poten-
tial RHBDL2 cleavage sites (Figure  1A). Because knowl-
edge about RHBDL2 substrates is sparse and the protease 
that cleaves the IL-11R in vivo is unknown, we sought to 
investigate whether the IL-11R is a substrate for RHBDL2 
or the other rhomboid family members. To this end, we co-
expressed IL-11R with one of the four RHBDL proteases in 
HEK293 cells and analyzed IL-11R proteolysis by western 
blotting. As shown in Figure 1B, co-expression of RHBDL2 
and IL-11R resulted in detectable soluble IL-11R (sIL-11R) 
in the cell culture supernatant and the appearance of IL-11R 
fragments of lower molecular weight in the cell lysate, both 
indicative of IL-11R proteolysis. Of note, this was not the 
case for RHBDL1, RHBDL3, and RHBDL4, suggesting that 
they were not capable of IL-11R cleavage (Figure 1B).
To show that the catalytic activity of the protease was re-
quired for IL-11R processing, we overexpressed IL-11R in 
combination with a catalytically inactive variant of RHBDL2 
(RHBDL2-SA) or RHBDL2 wild type (wt) and found no IL-
11R fragments of lower molecular weight in the cell lysate or 
sIL-11R release into the supernatant when RHBDL2 was cat-
alytically inactive (Figure 1C). Because the IL-6R shares the 
same overall topology with the IL-11R38 and the IL-6R has 
been previously identified as a substrate for RHBDL2,35 we 
tested whether IL-6R would be cleaved by a RHBDL family 
member and co-expressed the four proteases together with a 
myc-tagged IL-6R. While we could indeed detect a fragment 
of lower molecular weight in the cell lysate when IL-6R was 
co-expressed with RHBDL2, but not the other three proteases, 
we did not detect a striking amount of sIL-6R in the superna-
tant (Figure  1D). Instead, sIL-6R was secreted independent 
of RHBDL overexpression into the cell culture supernatant, 
consistent with previous reports of IL-6R on microvesicles.43 
Because RHBDLs are sensitive to the serine protease inhibitor 
3,4-dichloroisocoumarin (DCI),44 we observed reduced sIL-
11R generation by RHBDL2 when we preincubated cells with 
DCI (Figure 1E). Importantly, sIL-11R release by RHDBL2 
was insensitive to inhibition by the broad-spectrum metal-
loprotease inhibitor marimastat (MM) and the ADAM10-
specific inhibitor GI254023X (GI) (Figure 1F), proving that 
sIL-11R release was independent of ADAM10, which has 
been previously identified as an IL-11R sheddase.23-25 Neither 
DCI nor MM affected the viability of the cells (Figure 1G).
3.2 | Ala-370, but not Ala-367, is required 
for IL-11R proteolysis
The juxtamembrane region of the IL-11R contains two 
amino acid residues, which could potentially be RHBDL2 
cleavage sites: Ala-367 and Ala-370 (Figure 1A). In order 
to determine their contribution, we constructed and ana-
lyzed different IL-11R mutants (Figure  2A,B). We first 
used an IL-11R deletion variant (IL-11RΔV363_L372 
(Δ1),23), which lacks a stretch of 10 amino acid residues en-
compassing both alanine residues, and could neither detect 
sIL-11R release into the cell supernatant nor the genera-
tion of IL-11R cleavage fragments in the cell lysate when 
this IL-11R variant was expressed together with RHBDL2 
(Figure 2B). Importantly, a deletion variant lacking the 10 
amino acid residues directly N-terminal of the first deletion 
(IL-11RΔH353_S362 (Δ2),23) was cleaved by RHBDL2 in 
similar amounts as wt IL-11R, suggesting that the cleav-
age event took indeed place between Val-363 and Leu-372 
(Figure  2B). In order to determine which alanine residue 
was critical for IL-11R proteolysis, we replaced both in-
dividually by phenylalanine residues (IL-11R-A367F and 
IL-11R-A370F, respectively), because bulky amino acids at 
the P1 position have been previously reported to prevent 
RHBDL2 cleavage.31 Strikingly, while IL-11R-A367F was 
cleaved by RHBDL2, IL-11R-A370F showed barely any 
visible cleavage fragments in the cell lysate and only small 
amounts of sIL-11R in the cell culture supernatant, indi-
cating that Ala-370 is indeed critically involved in IL-11R 
proteolysis by RHBDL2 (Figure 2B).
To further substantiate this finding, we introduced ad-
ditional mutations into the IL-11R (Figure 2A). Insertion 
of the small amino acid residue glycine or the bulky amino 
acid residue tyrosine at position 367 had no striking ef-
fect on IL-11R proteolysis, confirming that Ala-367 is not 
involved in cleavage by RHBDL2 (Figure 2B). When we 
introduced the same amino acid residues at position 370 
(Figure  2A), the replacement of the alanine with glycine 
had no effect on IL-11R proteolysis, while the insertion 
of a tyrosine completely blocked IL-11R cleavage by 
RHBDL2 (Figure 2B). These data further support our as-
sumption that Ala-370 is located at the P1 position of the 
RHBDL2 cleavage site.
In order to ensure that our mutations did not alter cell sur-
face appearance of the IL-11R, which could potentially influ-
ence IL-11R cleavage by RHBDL2, we assessed cell-surface 
levels of the IL-11R by flow cytometry. As shown in 
Figure 2C,D, we did not find any significant difference of the 
different IL-11R variants at the cell surface, which indicates 
that the differences in sIL-11R generation indeed result from 
differential cleavage by RHBDL2. This was underlined by 
the fact that IL-11R-A370F, which showed impaired prote-
olysis by RHBDL2 (Figure 2B), was proteolytically cleaved 
by the metalloprotease ADAM10 at comparable levels as 
IL-11R wt (Figure  2E). In summary, our results show that 
IL-11R cleavage by RHBDL2 requires Ala-370 and uses a 
cleavage site that is distinct from the ADAM10 cleavage site, 
which is located further away from the membrane.23
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3.3 | Destabilizing amino acid residues 
in the TMH are critical for IL-11R proteolysis
The current understanding of substrate recognition of 
RHBDLs is that when the cleavage site is located within 
or in close proximity to the TMH, partial unfolding of the 
N-terminal part of the substrate TMH is required to ensure 
access of the catalytic center of the protease to the cleav-
age site of the substrate.45 Because the TMH of the IL-11R 
contains five amino acid residues with low hydrophobicity 
potentially destabilizing the TMH, namely Gly-373, Ser-376, 
Gly-379, Gly-383, and Gly-388, we constructed five different 
IL-11R variants in which one of these residues was mutated 
into a leucine to make the TMH more stable (Figure 3A). We 
expressed IL-11R wt and the five different mutants in com-
bination with RHBDL2 in HEK293 cells and investigated 
IL-11R proteolysis via western blot analysis. Intriguingly, 
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TMH-destabilizing amino acid that is three residues down-
stream of the actual cleavage site, displayed no cleavage 
fragment in the cell lysate and no sIL-11R was detectable in 
the cell culture supernatant, showing that this residue within 
the TMH was critical for IL-11R proteolysis (Figure  3B). 
Reduced proteolysis was also observed for the variants IL-
11R-S376L and IL-11R-G379L, while the last two mutants 
IL-11R-G383L and IL-11R-G388L were clearly proteolyti-
cally processed by RHBDL2 and did not differ substantially 
from cleavage of the IL-11R wt (Figure  3B). Like before, 
we ensured that all IL-11R variants were expressed at the 
cell surface via flow cytometry and again could not detect 
any major influence of the mutations on cell-surface appear-
ance of the IL-11R that would explain the altered proteolysis 
(Figure 3C,D). Our results show a critical role for destabiliz-
ing residues in the N-terminal part of the TMH for proteolysis 
of the IL-11R by RHBDL2. The farther these destabilizing 
residues are located from the actual cleavage site, the less 
severe appears to be their influence on the proteolysis.
3.4 | RHBDL2 can cleave and 
trigger secretion of IL-11R in the early 
secretory pathway
RHBDL2 has been described previously to be localized at 
the plasma membrane31,32 and ectopically expressed protein 
also resides within the ER.46 In order to determine where in 
the cell proteolysis of the IL-11R occurs, we analyzed ex-
pression of both proteins via fluorescence microscopy. As 
shown in Figure  4A, IL-11R expression was visible at the 
plasma membrane and in intracellular compartments, while 
upon overexpression RHDBL2 was predominantly detecta-
ble intracellularly and the amount at the cell surface appeared 
rather sparse. Therefore, we wondered whether IL-11R 
cleavage could also occur intracellularly. To this end, we co-
expressed RHBDL2 with either wild-type IL-11R, an IL-11R 
variant with an ER retention motif (IL-11R-KKSS), or the 
variant IL-11R-R296W, which contains a mutation found in 
a patient with craniosynostosis and is also retained within the 
ER.20 Indeed, we observed cleavage of the IL-11R-KKSS by 
RHBDL2 by western blotting of respective cell lysate and 
could further detect moderate amounts of sIL-11R in the cell 
supernatant of these cells (Figure  4B). We observed also 
cleavage of the IL-11R-R296W variant in the cell lysate, and 
longer exposure of the western blot further revealed a faint 
band of sIL-11R, although the molecular weight appeared to 
be smaller, suggesting that either RHBDL2 used a different 
cleavage site further N-terminal in this variant, or that im-
paired glycosylation caused the difference in the molecular 
weight (Figure  4B). Importantly, while these data clearly 
demonstrate that upon overexpression RHBDL2 can cleave 
the IL-11R within the ER, the resulting amount of sIL-11R 
in the tissue culture supernatant was significantly lower com-
pared to processing of wild-type IL-11R in the late secretory 
pathway (Figure 4B). To further substantiate this finding, we 
made use of an RHBDL2 variant fused to the KDEL ER re-
trieval motif (RHBDL2-KDEL) that ensures its efficient ret-
rograde transport from the cis-Golgi.47 When co-expressed 
with wild-type IL-11R, RHBDL2-KDEL cleaved the IL-11R 
to similar extend as the wild-type RHBDL2, which resulted 
in comparable sIL-11R release (Figure 4C). Importantly, this 
release required the catalytic activity of the protease, because 
both inactive variants RHBDL2-SA and RHBDL2-SA-
KDEL did not cleave the IL-11R (Figure 4C). In conclusion, 
our results show that proteolysis of the IL-11R by RHDBL2 
can occur already within the early secretory pathway and is 
not confined to the plasma membrane. While processing of 
the ER-retained IL-11R is moderate only, RHBDL2 cycling 
within the ER to Golgi intermediate triggers secretion as ef-
ficient as the wild-type rhomboid.
3.5 | RHBDL2-derived sIL-11R is 
biologically active
We have previously shown that a sIL-11R generated by 
ADAM10-mediated cleavage retains its ability to bind IL-11 
F I G U R E  2  RHDBL2 cleaves the IL-11R after Ala-370, but not after Ala-367. A, Juxtamembrane and transmembrane region of the human 
IL-11R (from Gln-351 to Gly-400) is depicted as IL-11R wt. The alanine residues representing two potential RHBDL2 cleavage sites are shown 
in bold font. Below the wild-type sequence, all other deletion variants and point mutations used in the experiments shown in this figure are listed. 
Modifications of the amino acid sequence in comparison to the IL-11R wild type are marked in red and bold font. B, All IL-11R variants listed 
in panel a were transiently transfected in HEK293 cells, either together with RHBDL2 or with mock control. Expression and proteolysis of the 
different IL-11R variants and expression of RHBDL2 were analyzed by western blotting of cell lysates. Actinin was visualized as loading control. 
sIL-11R was precipitated from cell culture supernatant by TCA precipitation and also analyzed by western blotting. C, D, Cell surface expression 
of the different IL-11R variants used in the experiment described in panel B was analyzed by flow cytometry. Shown are one representative 
experiment in panel C and the mean ± SD from three independent experiments in panel D. Expression of IL-11R wild type was set to 1 and the 
expression of all other variants calculated accordingly. E, HEK293 cells were transiently transfected with expression plasmids encoding IL-11R 
wild type, IL-11R-A370F, or left untransfected. Two days after transfection, medium was removed, cells were washed and stimulated in serum-free 
medium with 1 µM of the ionophore ionomycin for 60 minutes to activate ADAM10 or with DMSO as control. Proteolysis of the IL-11R variants 
was analyzed by western blot of cell lysates. Actinin was visualized as loading control. sIL-11R was precipitated from cell culture supernatant by 
TCA precipitation and also analyzed by western blot. SN: supernatant
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and that the resulting IL-11/sIL-11R complex is acting in an 
agonistic manner and is able to induce IL-11 trans-signal-
ing.23 To investigate whether sIL-11R generated by RHBDL2 
is similarly able to induce IL-11 trans-signaling, we made use 
of Ba/F3-gp130 cells, which are a murine pre-B cell line that 
proliferates upon stimulation with biologically active IL-11/
sIL-11R complexes, but undergoes apoptosis otherwise. Ba/
F3-gp130 cells incubated with supernatants of HEK293 cells 
F I G U R E  3  Helix-destabilizing amino acid residues within the TMH of the IL-11R are required for RHBDL2-mediated cleavage. A, 
Juxtamembrane and transmembrane region of the human IL-11R (from Gln-351 to Gly-400) is depicted as IL-11R wt. The RHBDL2 cleavage 
motif is shown in bold blue font. Potential destabilizing amino acid residues within the TMH are indicated in bold red font. A structural 
representation of the TMH with the N-terminal cleavage motif is shown above. Below the wild-type sequence, all point mutations used in the 
experiments shown in this figure are listed. Modifications of the amino acid sequence in comparison to the IL-11R wild type are marked in red 
and bold font. B, All IL-11R variants listed in panel a were transiently transfected in HEK293 cells, either together with RHBDL2 or with mock 
control. Expression and proteolysis of the different IL-11R variants and expression of RHBDL2 were analyzed by western blotting of cell lysates. 
Actinin was visualized as loading control. sIL-11R was precipitated from cell culture supernatant by TCA precipitation and also analyzed by 
western blot. C, D, Cell surface expression of the different IL-11R variants used in the experiment described in panel B was analyzed by flow 
cytometry. Shown are one representative experiment in panel C and the mean ± SD from three independent experiments in panel D. Expression of 
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transfected with wild-type IL-11R and RHBDL2 showed 
high proliferation when IL-11 was added, which was not 
the case without the cytokine (Figure 5A). Of note, super-
natant of HEK293 cells which were transfected with wild-
type IL-11R, but not RHBDL2, also induced proliferation 
in combination with IL-11 (Figure 5A), which is caused by 
the constitutive proteolysis of the IL-11R by ADAM10.23,24 
Supernatant of HEK293 cells transfected with either IL-11R-
R296W or IL-11R-KKSS alone did not induce proliferation 
(Figure 5A), as these variants are retained within the ER and 
do not undergo ADAM10-mediated cleavage (Figure  4B). 
Importantly, co-transfection of IL-11R-KKSS and RHBDL2 
resulted in a biologically active sIL-11R, whereas the traces 
of sIL-11R-R296W, detected upon RHBDL2 expression 
(Figure 4B), are biologically inactive (Figure 5A), consist-
ent with our previous findings.20 We further verified the 
biological activity of the sIL-11R by assessing the phospho-
rylation of STAT3 by western blot, and detected pSTAT3 
when Ba/F3-gp130 cells were stimulated with supernatant 
from cells overexpressing RHBDL2 and IL-11R wild type 
or IL-11R-KKSS (Figure 5B). In conclusion, these data dem-
onstrate that sIL-11R generated by RHBDL2 is biologically 
active and able to induce IL-11 trans-signaling.
3.6 | The mutation A370V prevents IL-11R 
proteolysis by RHBDL2
In order to determine whether the identified IL-11R cleav-
age site could have a functional impact in humans, we ana-
lyzed the Genome Aggregation Database (gnomAD,48) for 
homozygous carrier of coding mutations within the IL11RA 
F I G U R E  4  RHDBL2 can cleave the IL-11R in the early secretory pathway. A, HeLa cells were co-transfected with expression plasmids 
encoding IL-11R wild type and RHBDL2. Localization of both proteins was determined via fluorescence microscopy. B, IL-11R wild type, IL-11R 
with a C-terminal ER retention signal (IL-11R-KKSS) and the patient mutation IL-11R-R296W were transiently transfected in HEK293 cells, 
either together with RHBDL2 or with mock control. Expression and proteolysis of the different IL-11R variants and expression of RHBDL2 were 
analyzed by western blotting of cell lysates. Actinin was visualized as loading control. sIL-11R was precipitated from cell culture supernatant by 
TCA precipitation and also analyzed by western blot. C, IL-11R wild type was transiently transfected in HEK293 cells either with mock control 
or different RHBDL2 variants (RHBDL2 wt, RHBDL2-SA, RHBDL2-KDEL, and RHBDL2-KDEL-SA). The experiment was then conducted as 
described in panel b. SN: supernatant
(A) (B)
(C)
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gene. Indeed, gnomAD lists one homozygous carrier for the 
single nucleotide variant 9-34660537-C-T, which results in 
a substitution of Ala-370 into Val-370 (Figure 6A). Whether 
this mutation is associated with a human disease is unknown. 
To analyze whether this mutation has a functional conse-
quence on IL-11R proteolysis by RHDBL2, we constructed 
an expression plasmid with IL-11R-A370V variant and 
transfected it with and without co-transfection of RHDBL2 
into HEK293 cells. When compared to wild-type IL-11R, 
western blot analysis revealed that IL-11R-A370V was not 
cleaved by RHBDL2, and no sIL-11R released into the cell 
culture supernatant could be detected (Figure 6B). When we 
stimulated Ba/F3-gp130 cells with these supernatants with or 
without the addition of IL-11, we could clearly see STAT3 
phosphorylation of cells stimulated with supernatant from 
cells expressing wild-type IL-11R, but only a weak pSTAT3 
response of cells stimulated with supernatant from cells ex-
pressing IL-11R-A370V (Figure 6C). Importantly, the muta-
tion did not affect the biological function of the IL-11R per 
se, as IL-11R-A370V was transported to the cell surface of 
stably transduced Ba/F3-gp130 cells at comparable levels as 
IL-11R wild type (Figure 6D). Furthermore, Ba/F3-gp130-
IL-11R-A370V cells proliferated in a dose-dependent man-
ner (Figure 6E) and STAT3 was phosphorylated when cells 
were stimulated with IL-11 (Figure  6F). Thus, the rather 
small alteration within the cleavage site of a valine instead of 
an alanine residue appears to be already sufficient to prevent 
proteolysis by RHDBL2 and suggests that IL-11R cleavage 
by RHBDL2 is significantly reduced in the respective indi-
vidual annotated in the gnomAD, while IL-11 classic signal-
ing is intact.
4 |  DISCUSSION
Proteolysis of membrane-bound cytokine receptors has 
emerged as an important posttranslational modification over 
the years.21,22 This mechanism not only downregulates the 
amount of cytokine receptor at the cell surface, but also re-
duces the responsiveness of the cell toward activation by the 
F I G U R E  5  RHDBL2-derived sIL-11R is biologically active. A, Equal amounts of Ba/F3-gp130 cells were incubated in triplicate with 
supernatants of HEK293 cells that were transfected with either IL-11R wt, IL-11R-R296W, or IL-11R-KKSS, either together with control or with 
RHBDL2. Supernatant was either supplemented with recombinant IL-11 (500 ng/mL) or left untreated. Cells were incubated for 2 days and cell 
viability determined as described in Materials and Methods. Shown are the mean ± SD from one experiment out of three independent experiments 
with similar outcome. B, Equal amounts of Ba/F3-gp130 cells were stimulated for 15 minutes with the supernatants described in the legend of panel 
A and recombinant IL-11 was added were indicated. Phosphorylation of STAT3 was determined in cell lysates via western blot. Total STAT3 
levels and GAPDH were visualized to ensure equal protein loading
(A)
(B)
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cytokine ligand. Limited proteolysis also generates soluble 
cytokine receptors with distinct biological properties, which 
often differ from the functions of their membrane-tethered 
counterparts. Identification of the responsible proteases, their 
regulation, and understanding how specificity is achieved is 
therefore crucial, especially when considering anti-cytokine 
or anti-cytokine receptor therapeutics.26
In this study, we identify the IL-11R as a so far unrec-
ognized substrate of the rhomboid protease RHDBL2. We 
have previously shown that the IL-11R can be cleaved by 
the metalloprotease ADAM10,23,24 by the serine proteases 
neutrophil elastase and proteinase 323 and in overexpression 
by other metalloproteases, for example, meprin β.49 At least 
for ADAM10-mediated cleavage, the remaining IL-11R stub 
within the plasma membrane is further processed and de-
graded by the γ-secretase.25 Interestingly, we show that the 
IL-11R is not cleaved by the other members of the RHBDL 
family, namely RHBDL1, RHBDL3, and RHBDL4, indi-
cating that the four proteases do not share their substrates, 
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different from the ADAM family, in which, for example, 
ADAM10 and ADAM17 have a remarkable substrate overlap 
and, at least in part, can compensate for each other when one 
of the proteases is inactive.50,51
IL-6 is the most prominent member of the cytokine fam-
ily to which IL-11 belongs, and the IL-6R is also a substrate 
for different proteases, including ADAM10 and ADAM17.52 
The IL-6R has been recently reported in a proteomics screen 
as a RHBDL2 substrate,35 and we could indeed also detect an 
IL-6R cleavage fragment within the cell lysate when IL-6R 
and RHBDL2 were co-expressed. However, we did not ob-
serve significant release of sIL-6R into the cell culture super-
natant, indicating that the IL-11R is more efficiently cleaved 
by RHBDL2 than the IL-6R.
RHBDL2 is currently the family member for whom the 
most substrates have been described.30 We have identified 
the IL-11R as RHBDL2 substrate based on sequence sim-
ilarities between the membrane-proximal region of IL-11R 
and EGF.31 Strikingly, the EGF cleavage site contained an 
alanine residue at the P1 position, which is also present in 
the IL-11R. We could show that mutations of Ala-370 in the 
IL-11R critically modulate IL-11R proteolysis by RHBDL2. 
While the insertion of small amino acid residues was toler-
ated and did not alter sIL-11R generation, bulky amino acid 
residues prevented IL-11R proteolysis, and thus, sIL-11R re-
lease. Importantly, mutations of the residue Ala-367 did not 
influence IL-11R proteolysis by RHBDL2 at all, underlining 
not only that Ala-370 is indeed the specific cleavage site used 
by RHBDL2, but also rather showing that mutations within 
the IL-11R do not alter proteolysis per se. These data fit well 
into the concept that rhomboid proteases recognize a specific 
sequence surrounding the cleavage site.45
Besides the importance of the cleavage site, previous work 
had demonstrated that helix-destabilizing residues in the 
transmembrane region of the substrate are crucial for cleav-
age by rhomboids.53 We could also demonstrate this feature 
for the IL-11R by showing that mutation of certain TMH-
destabilizing amino acid residues within the transmembrane 
region blocks proteolysis by RHBDL2. Strikingly, the 
N-terminal half of the TMH close to the actual cleavage site 
was more important in this regard than the C-terminal por-
tion, which highlights an important regulatory mechanism 
buried within the TMH.
While the localization of endogenous RHBDL2 has not 
only been addressed yet, using ectopically expressed protein it 
has been reported to act mostly at the plasma membrane,31,32 
but also ER-based activity had been observed.46 However, 
processing of IL-11R confined to the ER by a C-terminal 
KKSS ER retention motif does not lead to efficient secretion. 
This indicates that ER-born cleavage products are retained 
by the ER quality control and ER-associated degradation 
pathway, like substrates that are cleaved by the ER-resident 
rhomboid protease RHBDL4.54 In contrast, RHBDL2 fused 
to a KDEL ER retrieval signal, which cycles between the ER 
and Golgi compartment, shows much higher processivity, in-
dicating that rhomboid proteases also can act as secretases 
of the early secretory pathway. One limitation of this study 
is the use of overexpressed proteins, and future work has to 
address whether also endogenous RHBDL2 plays a role in 
IL-11R secretion and in which cellular compartments endog-
enous RHBDL2 is localized.
The cytokine IL-11 has gained significant interest in 
recent years as an important regulatory protein in several 
human diseases, including gastrointestinal cancer9 and 
fibrosis.55 While most studies did not address whether 
classic or trans-signaling of IL-11 was responsible for the 
observed effects, our own studies with regard to female 
fertility,14 gastric cancer,8 and craniofacial bone develop-
ment20 point to classic signaling as the responsible mode 
of signaling. Thus, a functional role for IL-11 trans-sig-
naling in vivo has yet to be shown, although evidence for 
the existence of sIL-11R in vivo has been published.23,27 
Whether sIL-11R generation in vivo requires the activity 
of RHBDL2, ADAM10, or a different, yet, unidentified 
protease remains to be investigated. Nevertheless, IL-11 
trans-signaling increases the spectrum of cells that can be 
F I G U R E  6  The IL-11R variant IL-11R-A370V is biologically active, but not cleaved by RHBDL2. A, Juxtamembrane and transmembrane 
region of the human IL-11R (from Gln-351 to Gly-400) is depicted as IL-11R wt. The mutation A370V is indicated in bold red font. B, IL-11R 
wild type and the variant IL-11R-A370V were transiently transfected in HEK293 cells, either together with RHBDL2 or with mock control. 
Expression and proteolysis of the different IL-11R variants and expression of RHBDL2 were analyzed by western blotting of cell lysates. Actinin 
was visualized as loading control. sIL-11R was precipitated from cell culture supernatant by TCA precipitation and also analyzed by western blot. 
C, Equal amounts of Ba/F3-gp130 cells were stimulated for 15 minutes with the supernatants described in the legend of panel b and recombinant 
IL-11 was added were indicated. Phosphorylation of STAT3 was determined in cell lysates via western blot. Total STAT3 levels and GAPDH were 
visualized to ensure equal protein loading. D, Cell surface amounts of the IL-11R on Ba/F3-gp130, Ba/F3-gp130-IL-11R, and Ba/F3-gp130-IL-
11R-A370V cells were determined via flow cytometry. FACS plots depict one experiment out of three independent experiments. Control staining 
(ctl) was performed without the primary antibody. E, Equal amounts of Ba/F3-gp130-IL-11R-A370V cells were incubated in triplicate with 
increasing amounts (0.001-100 ng/mL) of either recombinant IL-11 or Hyper-IL-6 as indicated. Cells were incubated for 2 days and cell viability 
determined as described in Materials and Methods. Shown are the mean ± SD from one experiment out of three independent experiments with 
similar outcome. F, Equal amounts of Ba/F3-gp130-IL-11R and Ba/F3-gp130-IL-11R-A370V cells were stimulated for 15 minutes with 10 ng/mL 
Hyper-IL-6, 10 ng/mL IL-11, or left unstimulated. Phosphorylation of STAT3 was determined in cell lysates via western blot. Total STAT3 levels 
and GAPDH were visualized to ensure equal protein loading. SN: supernatant
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activated by IL-11 and holds the promise to represent an 
important pro-inflammatory pathway.
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